Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a ...

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine (NEJM) of positive results ...

– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...

In a report released yesterday, Matt Miksic from Barclays reiterated a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a ...

Stifel Nicolaus analyst Mathew Blackman maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target ...

SAN DIEGO, March 19, 2025--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England ...

Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults ... on the existing features of Tandem’s industry-leading Control ...

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are presently covering the company ...

Tandem Diabetes Care announced today that it launched its next-generation Control-IQ+ automated insulin delivery algorithm in ...